Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/digital-insomnia-therapy-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Sleep Health TechnologyDigital Insomnia Therapy Patents: Filing Trends and Leading Claimants
- 358 of 1,080 records sit with the top five assignees (33.1%) — concentration real but not dominant, leaving room for new entrants to stake out claims.
- Filings grew 88% from 2021 (80) to 2024 (150) before the count for 2022 peaked at 171, the highest year in the dataset so far.
- Only 6.9% of records touch G06F digital processing claims against 48.4% in A61K medicinal preparations — the software layer is thin relative to the pharmacological one.
1,080
Published Records
33%
Top-5 Share of All Records
+88%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (80 records) with 2024 (150) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,080 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What the digital insomnia therapy patent record shows
Digital insomnia therapy sits at the intersection of behavioral medicine and software: the corpus searched here combines cognitive behavioral therapy and sleep-coaching application claims with terms like sleep diary, adherence dropout, clinical outcome and reimbursement. That combination pulls in a field that is still substantially pharmacological — medicinal preparation and therapeutic-activity classes outnumber healthcare-informatics and data-processing classes by a wide margin. Filing activity across 2015–2026 shows sustained growth into the early 2020s with a single-year peak in 2022.
Because publication lags filing by roughly 18 months, the most recent one to two years in the trend understate real filing activity; the growth figure through 2024 is the more reliable read on momentum. Family counts, not raw document counts, are used throughout so that continuation filings and multi-jurisdiction duplicates do not inflate any single assignee's footprint.
Filing activity, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Data
Filing trend and technology composition
Two views of the same 1,080-record corpus: filings by year, and the IPC subclasses those filings carry.
Growth phase, then a plateau still filling in
Filings rose from 47 in 2017 to a peak of 171 in 2022, then eased toward 150 in 2024 — an 88% increase over the 2021-to-2024 span. 2025 and 2026 counts are still incomplete because of publication lag and should not be read as a decline.
Pharmacology still leads the classification mix
A61K (medicinal preparations, 48.4% of records) and A61P (therapeutic activity, 38.1%) dominate the classification mix, ahead of G01N material testing (20.2%), A61B diagnosis/surgery (16.6%) and G16H healthcare informatics (16.1%). G06F digital data processing trails at 6.9%, underscoring that most claims in scope are built around a compound or a diagnostic measurement rather than a software mechanism.
Shares are the percentage of the 1,080 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Digital Insomnia Therapy with Eureka
This page is one run against one query. Ask Eureka your own question about digital insomnia therapy and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
A representative claim and the most-cited prior art
Representative Record
Combination methods and compositions including sleep therapeutics for treating mood — US10758508B2
FEUERSTEIN, SETH
Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. Embodiments combine omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, potentially alongside antidepressants, to treat depression.Filed by Seth Feuerstein; granted 2020-09-01. Its claims sit at the boundary between pharmacological and behavioral sleep therapy — a boundary this dataset shows is still thinly claimed on the software side.
View full recordMost-cited records in the corpus
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2016110804A1 | Mobile wearable monitoring systems | 466 |
| 2 | US20210169417A1 | Mobile wearable monitoring systems | 450 |
| 3 | US20100324936A1 | Pharmacy management and administration with bedside real-time medical event data collection | 425 |
| 4 | US8348840B2 | Device and method to monitor, assess and improve quality of sleep | 200 |
| 5 | US20110190594A1 | Device and method to monitor, assess and improve quality of sleep | 181 |
| 6 | US20170262614A1 | Pharmacy management and administration with bedside real-time medical event data collection | 162 |
| 7 | US20120303388A1 | Pharmacy management and administration with bedside real-time medical event data collection | 116 |
| 8 | US20190189259A1 | Systems and methods for generating an optimized patient treatment experience | 110 |
| 9 | WO2020212951A1 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | 94 |
| 10 | US20200077942A1 | Stress reduction and sleep promotion system | 91 |
Citation counts favor older filings simply by virtue of time in the corpus; read them as a signal of influence on later filers, not as a ranking of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Four read-throughs from the concentration, trend and classification data above.
Concentration
33.1% of 1,080
held by the top five assignees
Leadership is real but not a lock
The top five assignees combined hold 358 of 1,080 records — a third of the field — while the leader alone accounts for 137. That leaves roughly two-thirds of filing activity spread across a long tail, including many single- or low-filing entrants.
Top 10 combined reach 42.6% of all records.
Momentum
+88%
2021 to 2024 filing growth
Growth is durable through the last complete year
Filings climbed from 80 in 2021 to 150 in 2024, an 88% increase, after peaking at 171 in 2022. That is genuine multi-year growth, not a single spike, even as the most recent one to two years understate true activity due to publication lag.
Peak year to date: 2022 at 171 filings.
Classification mix
6.9% vs 48.4%
G06F share vs A61K share
The software layer is thin against the pharmacology layer
Only 6.9% of records carry a G06F digital-processing class, against 48.4% for A61K medicinal preparations and 16.1% for G16H healthcare informatics. Claim space around personalization engines and adherence software is comparatively open.
G16H healthcare informatics sits at 16.1% of records.
Geography
345 US filings
vs 180 WIPO (PCT)
US filing leads, PCT and EPO follow
The United States receives the largest single share of filings at 345, ahead of WIPO/PCT at 180 and the EPO at 154, with Canada, Australia and Israel each in the mid-to-low double digits of records. That order suggests the US remains the primary venue for early filing decisions in this field.
Canada 96, Australia 94, Israel 53 records.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to digital insomnia therapy, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the gate sits open
The ranked leaders in this dataset cover 100 companies, counted by patent family. Filing concentration at the top leaves a wide field of adjacent, thinly claimed sub-areas.
Leader
137 families
single largest assignee
One assignee well ahead of the field
The top-ranked assignee holds 137 records, well clear of fifth place at 40 and tenth place at 18 — a steep early drop-off followed by a much flatter tail.
Fifth place: 40 records. Tenth place: 18 records.
Momentum
-20% to -100% YoY
latest-year change among tracked assignees
Recent-year activity is cooling across named leaders
Every assignee with visible recent-year momentum in this dataset shows a flat or negative year-over-year change, including drops to zero latest-year filings for several historically active names. That pattern is consistent with publication lag rather than a genuine pullback, since 2025–2026 records are still filling in.
Strongest recent filer still active: 4 records in the latest year.
Collaboration
10 co-assignee pairs
identified in the corpus
Co-filing is limited and concentrated
Only ten co-assignee pairs appear across the corpus, with the strongest pairing linked by 13 shared records. Collaborative filing is the exception rather than the norm in this field.
Second-strongest pair: 9 shared records.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Compass Pathfinder Ltd | 4 | -20% |
| 2A BIOSCIENCES INC | 2 | -50% |
| Abbott Laboratories | 0 | -100% |
| Alexander Shulgin Research Institute Inc. | 0 | -100% |
| Transcend Therapeutics Inc. | 0 | -100% |
| University of Virginia Patent Foundation | 0 | — |
| BURTON DAVID | 0 | -100% |
| Ieso Digital Health Ltd | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
Three directions for a team deciding where to file, litigate or partner next.
Stress-test the software white space
G06F and G16H claim density is low relative to A61K and A61P. Before filing a personalization-engine or adherence-tracking claim, check freedom-to-operate against the pharmacological patents that dominate the corpus, since some combination claims span both.
Explore the technology mapWatch the long tail, not just the leader
With 66.9% of records held outside the top five assignees, the competitive field is wider than headline concentration figures suggest. Track new entrants filing single or low-volume applications for early signals of a shifting sub-area.
Track assignee activityRe-read momentum after the lag clears
Recent-year year-over-year drops across tracked assignees likely reflect publication lag rather than a real slowdown. Revisit filing counts for 2025–2026 once those years have had time to fill in before drawing conclusions about pace.
Model filing trendsSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about digital insomnia therapy patents
It is moderately concentrated but not dominated by a single player. The top five assignees together hold 358 of 1,080 records in scope, or 33.1%, while the top ten reach 42.6%. That leaves well over half of all records spread across a long tail of smaller filers, which means the field is still open to new entrants rather than locked up by a handful of incumbents.
Yes, through the last complete filing year. Filings rose from 80 in 2021 to 150 in 2024, an 88% increase, with a single-year peak of 171 in 2022. Counts for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity, so those recent years should not be read as a slowdown.
Mostly pharmacological and diagnostic. A61K medicinal preparations appear on 48.4% of the 1,080 records and A61P therapeutic-activity claims on 38.1%, while G06F digital-processing claims appear on only 6.9% and G16H healthcare informatics on 16.1%. A record can carry more than one class, so these figures overlap, but the pattern is consistent: most claims in this search are built around a compound or a diagnostic measurement, not a software mechanism.
The clearest openings sit in the software and workflow layer rather than the pharmacological one, given how thin G06F and G16H coverage is relative to A61K and A61P. Adherence-dropout prediction, personalization-engine tuning logic, clinician-oversight dashboards and reimbursement-coded coaching workflows all show low claim density in this corpus. A first filing in one of these sub-areas would need to differentiate from existing sleep-diary and outcome-tracking prior art, but the classification data suggests fewer blocking claims than in the drug-combination space.
The United States is the largest single receiving office in this dataset at 345 records, ahead of WIPO/PCT filings at 180 and the European Patent Office at 154. Canada, Australia and Israel each account for meaningfully fewer records. That ordering is a useful signal of where competitors have prioritized protection, but a first-filing decision should also weigh where the applicant expects to commercialize and reimburse the therapy, since reimbursement pathways vary sharply by country in this sector.
Answers are grounded in the same dataset. Derived from a Patsnap search on Digital Insomnia Therapy covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Digital Insomnia Therapy in depth with Eureka
Go past this page: query the whole digital insomnia therapy corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.